Ifosfamide neurotoxicty in a young female with a remarkable response to ThiamineIMTIAZ, Saba; MUZAFFAR, Narjis.Journal of the Pakistan Medical Association. 2010, Vol 60, Num 10, pp 867-869, issn 0030-9982, 3 p.Article

Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animalsHANSEN, Ryan J; LUDEMAN, Susan M; PAIKOFF, Sari J et al.DNA repair. 2007, Vol 6, Num 8, pp 1145-1154, issn 1568-7864, 10 p.Article

Proceedings of a symposium on ifosfamide (Mitoxana^®; Holoxan^®) and mesna (Uromitexan^®), held at the De Vere Hotel, Coventry, U.K., 16-18 March 1983 = Comptes-rendus d'un symposium sur l'ifosfamide (Mitoxana; Holoxan) et le mesna (Uromitexan) tenu à l'hôtel De Vere, Coventry, Royaume Uni, 16-18 mars 1983HELLMANN, K.Cancer treatment reviews. 1983, Vol 10, issn 0305-7372, 192 p., suppl. AConference Proceedings

Expression of CD40 has no predictive value in soft tissue sarcomasOTTAIANO, A; PISANO, C; DE CHIARA, A et al.Anticancer research. 2003, Vol 23, Num 2B, pp 1597-1604, issn 0250-7005, 8 p.Article

Dose finding of ifosfamide administered with a chronic two-week continuous infusionCARTEI, G; CLOCCHIATTI, L; SACCO, C et al.Oncology. 2003, Vol 65, pp 31-36, issn 0030-2414, 6 p., SUP2Conference Paper

STRUCTURES OF TWO ISOMERIC BICYCLIC DERIVATIVES OF 4-HYDROPEROXYISOPHOSPHAMIDECAMERMAN N; FAWCETT JK; CAMERMAN A et al.1983; JOURNAL OF MEDICINAL CHEMISTRY; ISSN 0022-2623; USA; DA. 1983; VOL. 26; NO 5; PP. 683-686; BIBL. 9 REF.Article

Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamideKAIJSER, G. P; KEIZER, H. J; BEIJNEN, J. H et al.Anticancer research. 1996, Vol 16, Num 5B, pp 3247-3257, issn 0250-7005Conference Paper

Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignanciesKIEWE, Philipp; NEUMANN, Martin; WAGNER, Thomas et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 1, pp 27-33, issn 0344-5704, 7 p.Article

Long term renal toxicity of ifosfamide in adult patients ― 5 year dataFARRY, James K; FLOMBAUM, Carlos D; LATCHA, Sheron et al.European journal of cancer (1990). 2012, Vol 48, Num 9, pp 1326-1331, issn 0959-8049, 6 p.Article

Ifosfamide associated myoclonus-encephalopathy syndromeSAVICA, Rodolfo; RABINSTEIN, Alejandro A; JOSEPHS, Keith A et al.Journal of neurology. 2011, Vol 258, Num 9, pp 1729-1731, issn 0340-5354, 3 p.Article

Pharmacology of ifosfamideFURLANUT, M; FRANCESCHI, L.Oncology. 2003, Vol 65, pp 2-6, issn 0030-2414, 5 p., SUP2Conference Paper

Antiblastic drug combinations with ifosfamide: An updateFULFARO, F; VALERIO, M. R; BADALAMENTI, G et al.Oncology. 2003, Vol 65, pp 21-30, issn 0030-2414, 10 p., SUP2Conference Paper

Ifosfamide in germ cell tumorsEINHORN, L. H.Oncology. 2003, Vol 65, pp 73-75, issn 0030-2414, 3 p., SUP2Conference Paper

Effects of single dose administration of ifosfamide on testes and semen characteristics in the rabbitYPSILANTIS, Petros; PAPAIOANNOU, Nikolaos; PSALLA, Dimitra et al.Reproductive toxicology (Elmsford, NY). 2003, Vol 17, Num 2, pp 237-245, issn 0890-6238, 9 p.Article

Investigations on the pharmacokinetics of trofosfamide and its metabolites: first report of 4-hydroxy-trofosfamide kinetics in humansPREISS, Rainer; BAUMANN, Frank; STEFANOVIC, Dragan et al.Cancer chemotherapy and pharmacology. 2004, Vol 53, Num 6, pp 496-502, issn 0344-5704, 7 p.Article

Ifosfamide in thymic neoplasmsDANIELE, O; FORNASIERO, A.Oncology. 2003, Vol 65, pp 44-45, issn 0030-2414, 2 p., SUP2Conference Paper

Design of new oxazaphosphorine anticancer drugsJUN LIANG; MIN HUANG; WEI DUAN et al.Current pharmaceutical design. 2007, Vol 13, Num 9, pp 963-978, issn 1381-6128, 16 p.Article

Influence of age upon ifosfamide-induced nephrotoxicityMCCUNE, Jeannine S; FRIEDMAN, Debra L; SCHUETZE, Scott et al.Pediatric blood & cancer. 2004, Vol 42, Num 5, pp 427-432, issn 1545-5009, 6 p.Article

Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patientsJACOT, William; PUJOL, Jean-Louis; CHAKRA, Mohammad et al.Lung cancer. 2012, Vol 75, Num 2, pp 213-216, issn 0169-5002, 4 p.Article

Variations in schedules of ifosfamide administration : a better understanding of its implications on pharmacokinetics through a randomized cross-over studyBRAIN, E. G. C; REZAI, K; WEILL, S et al.Cancer chemotherapy and pharmacology. 2007, Vol 60, Num 3, pp 375-381, issn 0344-5704, 7 p.Article

Ifosfamide neurotoxicity : An atypical presentation with psychiatric manifestationsKERDUDO, C; ORBACH, D; SARRADET, J. L et al.Pediatric blood & cancer. 2006, Vol 47, Num 1, pp 100-102, issn 1545-5009, 3 p.Article

The effect of N-acetylcysteine on the antitumor activity of ifosfamideCHEN, Nancy; HANLY, Lauren; RIEDER, Michael et al.Canadian journal of physiology and pharmacology. 2011, Vol 89, Num 5, pp 335-343, issn 0008-4212, 9 p.Article

Ifosfamide pharmacokinetics and hepatobiliary uptake in vivo investigated using single- and double-resonance ³¹P MRSMANCINI, Laura; PAYNE, Geoffrey S; DZIK-JURASZ, Andrzej S. K et al.Magnetic resonance in medicine. 2003, Vol 50, Num 2, pp 249-255, issn 0740-3194, 7 p.Article

Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancerWILLITS, I; PRICE, L; PARRY, A et al.British journal of cancer. 2005, Vol 92, Num 9, pp 1626-1635, issn 0007-0920, 10 p.Article

Determination of 4-hydroxyifosfamide concomitantly with ifosfamide and its dechloroethylated metabolites using gas chromatography and a nitrogen phosphorus-selective detectorGOURMEL, B; GRANVIL, C. P; DENIS, S. L et al.Journal of chromatography. B, Biomedical sciences and applications. 1999, Vol 732, Num 1, pp 3-15, issn 1387-2273Article